Can afamelanotide and elagolix be used together?

There is no clinical rationale or approved data for co-administering these compounds, as they target completely different conditions and pathways. If you have both EPP and endometriosis, you'd need separate treatments—but this is extremely rare. Discuss combination therapy only with a healthcare provider familiar with both conditions.

Which has more side effects?

Both are generally well-tolerated. Afamelanotide's main concerns are injection-site reactions and skin darkening. Elagolix's primary concern is reversible hormonal suppression (hot flashes, night sweats, headache) and potential bone density impacts with prolonged use. Severity varies by individual; consult your prescriber for personalized risk assessment.

Is one more expensive than the other?

We don't provide pricing information, as costs vary by region, insurance, and formulary status. Both are specialty pharmaceuticals with significant acquisition costs. Contact your healthcare provider or pharmacist for current pricing and insurance coverage details.

What if I live outside the US, EU, or Canada?

Regulatory approval varies by country. Afamelanotide is approved in the US and EU; elagolix in the US and Canada. Availability in other regions (e.g., Australia, Japan, UK) may differ. Check with your local health authority or a healthcare provider in your country for what's available.

Are there newer alternatives to either?

For EPP, afamelanotide remains the primary approved option. For endometriosis, other GnRH antagonists and selective progesterone receptor modulators (SPRMs) are in development or approved in some regions. Discuss current treatment landscape with your specialist, as guidelines evolve.

Afamelanotide vs Elagolix: Key Differences & Uses

Afamelanotide and elagolix are both FDA-approved compounds, but they work through completely different mechanisms and treat entirely different conditions. Afamelanotide is a melanocortin receptor agonist designed to stimulate melanin production and protect skin from UV damage—it's used for erythropoietic protoporphyria (EPP), a rare genetic disorder. Elagolix, by contrast, is a GnRH antagonist that suppresses reproductive hormones and is approved for moderate-to-severe endometriosis-associated pain in people assigned female at birth. Understanding their distinct targets, regulatory pathways, and clinical evidence helps clarify why they're not interchangeable—and which one (if either) might be relevant to your situation.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide that acts as an agonist at melanocortin-1 (MC1) receptors, stimulating the body's natural melanin production pathway. The compound was developed to address a specific and rare genetic disorder: erythropoietic protoporphyria (EPP), a condition in which patients accumulate toxic porphyrin compounds in their skin and develop severe phototoxicity upon sun exposure.

The drug is administered as a weekly subcutaneous implant. By increasing baseline melanin levels and thickening the stratum corneum, afamelanotide helps reduce the skin's photosensitivity—allowing patients with EPP to tolerate greater sun exposure without triggering painful blistering and burning. Clinical trial data showed that combined afamelanotide and beta-carotene therapy reduced phototoxic reactions by approximately 50% in patients with EPP.

Regulatory Status of Afamelanotide

Afamelanotide received FDA approval in 2014 under the brand name Scenesse, and was subsequently authorised by the EMA. It is not approved by Health Canada. Given the rarity of EPP, the compound qualified for orphan drug designation in both the US and EU, reflecting its ultra-niche therapeutic indication.

The peptide's approval was based on 23 clinical trials documenting efficacy and safety, with the primary endpoints focused on patient-reported phototoxic reactions and time spent outdoors.

What Is Elagolix?

Elagolix is a small-molecule GnRH (gonadotropin-releasing hormone) receptor antagonist. Unlike afamelanotide's targeted role in melanin signalling, elagolix acts centrally to suppress the pituitary-gonadal axis, rapidly reducing circulating estrogen and progesterone levels. This hormonal suppression is the mechanism behind its use in endometriosis: by lowering endogenous hormone production, the drug reduces the growth and activity of ectopic endometrial lesions, thereby alleviating pain.

Elagolix is administered orally, twice daily, and was approved by the FDA in 2018 for moderate-to-severe endometriosis-associated pain in premenopausal women. The compound shows rapid symptom relief, with some patients experiencing meaningful pain reduction within the first month of treatment.

Regulatory Status of Elagolix

Elagolix gained FDA approval in 2018 and was subsequently approved by Health Canada. It is not authorised by the EMA, reflecting regional regulatory differences in risk-benefit assessment for hormonal therapies in endometriosis. The approval pathway involved 31 clinical trials, including the landmark ELARIS studies that demonstrated efficacy in reducing both dysmenorrhea and non-menstrual pelvic pain.

Head-to-Head: Key Differences

Mechanism of Action

Afamelanotide works peripherally via melanocortin signalling—it's fundamentally about melanin and skin biology.

Elagolix works centrally via hormonal suppression—it's fundamentally about reproductive endocrinology.

These are not comparable mechanisms. One does not substitute for the other.

Indication & Patient Population

Afamelanotide: Erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder affecting the heme biosynthesis pathway. Patients are typically diagnosed in childhood and struggle with sun sensitivity throughout their lives.

Elagolix: Moderate-to-severe endometriosis-associated pain, a far more common condition affecting roughly 10% of reproductive-age women globally. The indication specifically covers people assigned female at birth with confirmed or suspected endometriosis.

Route & Frequency

Afamelanotide: Weekly subcutaneous implant (sustained-release formulation placed under the skin).

Elagolix: Oral tablet, twice daily (BID dosing).

Regulatory Geographic Reach

| Region | Afamelanotide | Elagolix | |--------|---------------|----------| | United States | FDA-approved (Scenesse) | FDA-approved (Orilissa) | | European Union | EMA-authorised | Not authorised | | Canada | Not approved | Health Canada–approved (Oriahnn) |

Clinical Evidence Volume

Both compounds have strong evidence bases. Elagolix has a slightly larger trial portfolio (31 trials vs. 23), but both are Grade A compounds with rigorous Phase 3 data supporting their respective approvals. The ELARIS RCTs for elagolix demonstrated clinically meaningful reductions in dysmenorrhea and pelvic pain versus placebo. Similarly, afamelanotide trials showed consistent reductions in phototoxic reactions in EPP patients.

Who Is Each Best Suited For?

Afamelanotide Is Right If:

You have a confirmed diagnosis of erythropoietic protoporphyria.
You live in the US or EU (regulatory availability).
You're willing to receive weekly subcutaneous implants.
You want to increase your tolerance for natural sunlight without ongoing pharmaceutical side effects tied to systemic hormone suppression.
You prioritize a mechanism directly targeting skin photoprotection.

Elagolix Is Right If:

You have confirmed or suspected endometriosis with moderate-to-severe pain.
You live in the US or Canada (regulatory availability).
You're comfortable with twice-daily oral dosing.
You can tolerate reversible hormonal suppression (reduced estrogen/progesterone) for pain management.
You're willing to monitor for potential bone density changes with long-term use (standard for GnRH antagonists).
You want rapid symptom relief (often within weeks, not months).

Related Compounds & Glossary

If you're exploring peptide therapies, you might also be interested in octreotide, a different peptide agonist used in neuroendocrine conditions, or teriparatide, which, like elagolix, modulates a central endocrine axis. For more on how peptides target hormone signalling, see our glossary entries on agonists and receptor signalling.

Another hormone-modulating compound worth comparing is leuprolide, a GnRH agonist (note: agonist, not antagonist) also used in endometriosis but via a different temporal mechanism than elagolix.

Bottom Line

Afamelanotide and elagolix are both approved, evidence-backed compounds—but they serve entirely different medical populations and work through unrelated biological pathways. Afamelanotide is a niche, orphan-indication drug for a rare genetic disorder affecting skin photosensitivity; elagolix is a more broadly applicable endocrine agent for a common gynecological pain condition. Neither is a substitute for the other. Your choice depends entirely on your diagnosis, geography, and tolerance for each drug's specific side effect profile and administration method.

Afamelanotide vs Elagolix: A Detailed Comparison